The deadline to apply for scholarships has been extended to 15 September 2014.

Multi-site study underway in Africa

The Handbook has been developed for the purpose of describing ways to implement established WHO policies relevant for the management of MDR-TB.

Laia Ruiz Mingote and Dorothy Namutamba—co-chairs of CRAG— and Mike Watson Frick—TB/HIV Program Officer at Treatment Action Group—discuss the benefits and risks of using bedaquiline to treat TB.

Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis.

Ukraine has one of the worst TB problems in Europe, second only to Russia in terms of infection numbers. It is one of 27 high MDR-TB burden countries in the world.

The handbook shows how to use various data sources, presents existing tools to analyse the quality of data and describes methods to estimate the burden of TB and related trends.

The GCTA is a coalition of representatives from and of the TB affected communities aiming to bring together activists from diverse backgrounds and regions to ensure TB affected communities are at the center of all processes on TB.

Several community groups express concerns regarding the STREAM stage II trial design for bedaquiline approval.

A new research report from ACTION global health shows that joint TB-HIV activities are neglected by HIV programs and overwhelmingly carried out by TB programs, and that global guidelines to address TB-HIV have not been prioritized by leading donors and affected countries.